Development
NeuroOne Medical Technologies Corporation
NMTC
$0.5817
-$0.0073-1.24%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -22.86% | 60.74% | 2,787.16% | 2,075.63% | 1,828.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -22.86% | 60.74% | 2,787.16% | 2,075.63% | 1,828.00% |
| Cost of Revenue | 55.37% | 63.14% | 61.57% | 49.63% | 34.92% |
| Gross Profit | -191.02% | -64.81% | 35.23% | 40.07% | 48.35% |
| SG&A Expenses | 7.75% | -0.76% | 7.79% | -5.60% | 1.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.40% | 26.43% | 30.00% | 15.21% | 14.29% |
| Operating Income | -50.58% | -19.19% | 9.61% | 18.24% | 17.26% |
| Income Before Tax | -50.94% | -18.60% | 10.38% | 18.07% | 17.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.94% | -18.60% | 10.38% | 18.07% | 17.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.94% | -18.60% | 10.38% | 18.07% | 17.33% |
| EBIT | -50.58% | -19.19% | 9.61% | 18.24% | 17.26% |
| EBITDA | -50.28% | -18.60% | 10.27% | 18.82% | 17.79% |
| EPS Basic | -25.63% | -5.30% | 20.81% | 31.23% | 36.13% |
| Normalized Basic EPS | -25.38% | -5.03% | 21.59% | 31.95% | 36.16% |
| EPS Diluted | -25.63% | -5.30% | 20.81% | 31.23% | 36.13% |
| Normalized Diluted EPS | -25.38% | -5.03% | 21.59% | 31.95% | 36.16% |
| Average Basic Shares Outstanding | 23.80% | 13.26% | 11.15% | 17.13% | 28.15% |
| Average Diluted Shares Outstanding | 23.80% | 13.26% | 11.15% | 17.13% | 28.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |